Is ADCC the biggest challenge to your biosimilar?
3
Is ADCC the biggest challenge to your biosimilar?
-
Upload
sartorius-stedim-biooutsource -
Category
Science
-
view
125 -
download
0
Transcript of Is ADCC the biggest challenge to your biosimilar?
Is ADCC the biggest challenge to your biosimilar?
2
Introduction
Sartorius Stedim Biotech (SSB) BioOutsource released a new video, that is now available on-line explaining how to overcome the issues associated with using antibody-dependent cell-mediated cytotoxicity (ADCC) assays. The bite-sized video outlines the factors affecting the use of ADCC assays and discusses what to consider when determining comparability and designing biosimilar drugs.
In just five minutes, bioassay development experts, Dr. Catriona Thomson and Dr. Daniel Galbraith describe in this engaging video the challenges of using ADCC assays and explain when to use the different types of assay to assess biosimilars. To watch the video please proceed to the next slide.
3
Any Questions?
Contact us (By Phone): Sartorius Stedim BioOutsource Limited1 Technology Terrace,Todd Campus,West of Scotland Science Park,Glasgow, G20 0XA.Reception: +44 (0)141 946 4222Sales: +44 (0)141 948 1291
Contact us (By Web): http://www.biooutsource.com/contact-us/
